Cataract surgery combined with 0,7mg intravitreal dexamethasone implant in diabetic patients with pre-existent macular edema: our experience
Session Details
Session Title: Combined Cataract Surgery: Techniques/Practice Styles
Session Date/Time: Tuesday 13/09/2016 | 14:00-16:00
Paper Time: 14:30
Venue: Auditorium C6
First Author: : G.Addabbo ITALY
Co Author(s): : F. Pignatelli F. Prima
Abstract Details
Purpose:
To retrospectively study the efficacy of a single 0.7mg dexamethasone intravitreal implant simultaneously phacoemulsification and IOL implant in diabetic patients with pre-existent macular edema
Setting:
Department of ophtalmology, St J. Moscati Hospital, Taranto, Italy.
Methods:
78 eyes of 54 patients with diabetic macular edema and cataract were retrospectivly reviewed. 40 eyes (group A) underwent standard cataract surgery while 38 eyes (group B) underwent cataract surgery and intravitreal injection of 0.7-mg dexamethasone implant at the same time. All surgeries were performed by the same surgeon, phacoemulsification with IOL implant was the technique of choise. Best-corrected visual acuity (BCVA), central retinal thickness (CRT) intraocular pressure (IOP) was evaluated at baseline, 1 month and 6 motnhs.
Results:
After a mean follow-up of 6 months, in gruop A mean BCVA increased from 0,53 logmar to 0,44 logmar (P= 0,1) , mean CRT increased from 264 µm to 337µm (P= 0,005), whie IOP did not change significantly. In gruop B mean BCVA was signicantly increased from 0,58 logmar to 0,20 logmar (P< 0,00001) , mean CRT decreased from 305,19 µm to 224,24 µm (P= 0,05), whie IOP did not change significantly. Mean BVCA in group B compared to group A was significantly better (0,20 logmar vs 0,44logmar P<0,0001) and mean CRT was significantly lower ( 224,24 µm to 337,23 µm P=0,001). No postoperatives complications were observed.
Conclusions:
Our results strongly suggest that a single injection of 0.7 mg dexamethasone intravitreal implant combined with phacoemuslification and IOL implant is a safe and effective approach for those patient with cataract and diabetic maculare edema.
Financial Disclosure:
NONE